EW · 10-Q · 2026Q2 · Full report

Operating Expense Trends

Edwards Lifesciences Corp · 2026-08-04 · Importance 24 · Surprise 14

SG&A expense increased during the three and six months ended June 30, 2026 because of higher headcount-related expenses and commercial activities supporting patient care. Foreign-currency movements increased SG&A by $6.0 million in the second quarter and $20.6 million in the first six months, primarily because the U.S. dollar weakened against the euro. R&D expense also increased year over year as Edwards invested in implantable heart-failure management and advanced technology innovation. Six-month litigation expense increased to $43.4 million from $26.4 million, an increase of $17.0 million, for legal, intellectual-property, and tax proceedings.

Key facts

• R&D expenses increased for the three and six months ended June 30, 2026 primarily due to increased investments in implantable heart failure management and advanced technology innovation. source
• Other operating income was $11.0 million and $25.2 million in the three and six months ended June 30, 2026, and included income from transition services agreements of $11.5 million and $24.7 million, respectively. source
• Foreign currency exchange rate fluctuations increased SG&A expenses by $6.0 million and $20.6 million during the three and six months ended June 30, 2026, respectively. source
• Interest income, net was $30.0 million and $63.5 million for the three and six months ended June 30, 2026, respectively, and $37.4 million and $73.9 million for the three and six months ended June 30, 2025, respectively. source
• SG&A expenses increased for the three and six months ended June 30, 2026 primarily due to higher headcount related expenses and commercial activities to support patient care. source